Jagsonpal Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication for Unaudited Financial Results for quarter ended June 30, 2025
JAGSNPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Jagsonpal Pharmaceuticals has filed copies of newspaper advertisements published on July 28, 2025 in Business Standard (English and Hindi), as required under Regulation 47 of SEBI's Listing Obligations and Disclosure Requirements. The advertisement contains extracts of the company's unaudited financial results for Q1 FY26 (quarter ended June 30, 2025). Key numbers from the published extract: Total Income from Operations rose to Rs. 784.37 lakhs (up from Rs. 628.83 lakhs in Q1 FY25), Profit Before Tax came in at Rs. 144.31 lakhs (vs Rs. 103.95 lakhs YoY), and Profit After Tax jumped to Rs. 107.95 lakhs (vs Rs. 53.29 lakhs YoY). Basic EPS for the quarter stood at Rs. 1.60 versus Rs. 0.78 in the same quarter last year. The filing was signed by Company Secretary Pratham Rawal.
This is a routine compliance filing confirming that the Q1 FY26 results have been published in newspapers as mandated. The underlying numbers, however, show strong year-on-year growth — revenue up about 25% and net profit roughly doubling — which is a positive signal for shareholders.